11.15.24 -- Regeneron's Strategy To Address Congenital Deafness

The "Australian Advantage" approach offers U.S. biotech firms numerous benefits, including a cash rebate of almost 50%, faster timelines, no IND requirement, and globally accepted data.

To provide a deeper understanding of successful study design, this author guides readers through study personas, core design, a seven-step process for post-go-live (PGL) changes, and more.

What causes otherwise normal, healthy immune cell populations to go bad? Isaac Stoner, CEO and Co-Founder at Octagon Therapeutics explains the strategy behind maintaining chronic immune health.

In-home clinical trial visits yield major benefits for patients, including increased access and convenience. As a result, hybrid trials are helping developers increase enrollment, engagement, and retention.

While exploring a novel therapeutic protein (TP) in 48 healthy volunteers, several technical calls were required so the study could begin running promptly.

Uncover how this optimized process ensures consistency in cell viability and recovery while preserving immune cell populations across multiple donor samples.